Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.

Schwab N, Schneider-Hohendorf T, Hoyt T, Gross CC, Meuth SG, Klotz L, Foley JF, Wiendl H.

Mult Scler. 2018 Apr;24(5):563-573. doi: 10.1177/1352458517728814. Epub 2017 Aug 29.

PMID:
28847222
2.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.

Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I.

Lancet Neurol. 2017 Nov;16(11):925-933. doi: 10.1016/S1474-4422(17)30282-X. Epub 2017 Sep 29.

PMID:
28969984
3.

Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.

Carruthers RL, Chitnis T, Healy BC.

Mult Scler. 2014 May;20(6):757-60. doi: 10.1177/1352458513509509. Epub 2013 Nov 4.

PMID:
24189572
4.

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.

Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.

Mult Scler. 2015 Oct;21(12):1600-3. doi: 10.1177/1352458514567728. Epub 2015 Feb 6.

PMID:
25662344
5.

Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.

Achiron A, Miron G, Zilkha-Falb R, Magalashvili D, Dolev M, Stern Y, Gurevich M.

J Neurovirol. 2016 Dec;22(6):736-746. Epub 2016 May 11.

PMID:
27170332
6.

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B.

Ann Neurol. 2014 Dec;76(6):802-12. doi: 10.1002/ana.24286. Epub 2014 Oct 24.

7.

JCV serology in time: 3 years of follow-up.

Cambron M, Hadhoum N, Duhin E, Lacour A, Chouraki A, Vermersch P.

Acta Neurol Scand. 2017 Jul;136(1):54-58. doi: 10.1111/ane.12699. Epub 2016 Oct 20.

PMID:
27766611
8.

Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population.

Correia I, Jesus-Ribeiro J, Batista S, Martins AI, Nunes C, Macário MC, Cunha L, Sousa L.

J Clin Neurosci. 2017 Nov;45:257-260. doi: 10.1016/j.jocn.2017.08.006. Epub 2017 Aug 24.

PMID:
28844615
9.

The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings.

Kolcava J, Hulova M, Benesova Y, Bednarik J, Stourac P.

Mult Scler Relat Disord. 2019 May;30:187-191. doi: 10.1016/j.msard.2019.02.019. Epub 2019 Feb 14.

PMID:
30785075
10.

JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.

Lanzillo R, Liuzzi R, Vallefuoco L, Moccia M, Amato L, Vacca G, Vacchiano V, Portella G, Brescia Morra V.

Ther Clin Risk Manag. 2014 Oct 9;10:807-14. doi: 10.2147/TCRM.S63295. eCollection 2014.

11.

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.

van Kempen ZLE, Leurs CE, de Vries A, Vennegoor A, Rispens T, Wattjes MP, Killestein J.

Eur J Neurol. 2017 Sep;24(9):1196-1199. doi: 10.1111/ene.13355. Epub 2017 Jul 14.

PMID:
28707781
12.

PML risk stratification using anti-JCV antibody index and L-selectin.

Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H.

Mult Scler. 2016 Jul;22(8):1048-60. doi: 10.1177/1352458515607651. Epub 2015 Oct 2.

PMID:
26432858
13.

Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.

Dominguez-Mozo MI, Rus M, Santiago JL, Izquierdo G, Casanova I, Galan V, Garcia-Martinez MA, Arias-Leal AM, García-Montojo M, Pérez-Pérez S, Arroyo R, Alvarez-Lafuente R.

Eur J Clin Invest. 2017 Feb;47(2):158-166. doi: 10.1111/eci.12721.

PMID:
28036121
14.

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values.

Schwab N, Schneider-Hohendorf T, Pignolet B, Breuer J, Gross CC, Göbel K, Brassat D, Wiendl H.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(1):e195. doi: 10.1212/NXI.0000000000000195. eCollection 2016 Feb.

15.

Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.

Domínguez-Mozo MI, García-Montojo M, Arias-Leal A, García-Martínez Á, Santiago JL, Casanova I, Galán V, Arroyo R, Fernández-Arquero M, Alvarez-Lafuente R.

Eur J Neurol. 2016 Jan;23(1):182-9. doi: 10.1111/ene.12834. Epub 2015 Oct 25.

PMID:
26498276
16.

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.

Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.

Neurology. 2012 May 29;78(22):1736-42. doi: 10.1212/WNL.0b013e3182583022. Epub 2012 May 16.

PMID:
22592369
17.

Natalizumab therapy is associated with changes in serum JC virus antibody indices over time.

Peters J, Williamson E.

J Neurol. 2017 Dec;264(12):2409-2412. doi: 10.1007/s00415-017-8643-4. Epub 2017 Oct 16.

PMID:
29034436
18.

Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis.

Borie D, Kremer JM.

Semin Arthritis Rheum. 2015 Oct;45(2):163-6. doi: 10.1016/j.semarthrit.2015.06.003. Epub 2015 Jun 17. Review.

19.

Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.

Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani MP, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, Rinaldi F, Barzon L, Militello V, Pizzorno M, Bandini F, Capello E, Palù G, Uccelli A, Mancardi GL, Varnier OE.

J Neuroimmune Pharmacol. 2012 Sep;7(3):665-72. doi: 10.1007/s11481-012-9366-z. Epub 2012 May 16.

PMID:
22585413
20.

Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study.

Auer M, Hegen H, Sellner J, Oppermann K, Bsteh G, Di Pauli F, Berger T, Deisenhammer F.

Brain Behav. 2019 Jul;9(7):e01332. doi: 10.1002/brb3.1332. Epub 2019 Jun 6.

Supplemental Content

Support Center